Hunan Hansen Pharmaceutical (002412.SZ): Simotang Oral Liquid Receives Drug Clinical Trial Approval
Hunan Hansen Pharmaceutical (002412.SZ) announced that the company recently received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for Simotang Oral Liquid for additional indications, approving the conduct of clinical trials of this product for non-erosive reflux disease.
Hunan Hansen Pharmaceutical (002412.SZ) announced that the company recently received the "Drug Clinical Trial Approval Notice" issued and approved by the National Medical Products Administration regarding the addition of indications for Simotang Oral Liquid, agreeing to conduct clinical trials of this product for non-erosive reflux disease.
Related Articles
US Stock Market Move | Storage sector strengthens collectively; Western Digital Corporation (WDC.US) rises over 8%.
Eli Lilly (LLY.US) Weight-Loss Oral Drug Foundayo Shows Significant Efficacy in Treating Sleep Apnea; Plans to Seek FDA Approval by Year-End
A-share Evening Highlights | Iran signals willingness to negotiate! Oil prices plunge, gold rallies
US Stock Market Move | Storage sector strengthens collectively; Western Digital Corporation (WDC.US) rises over 8%.
Eli Lilly (LLY.US) Weight-Loss Oral Drug Foundayo Shows Significant Efficacy in Treating Sleep Apnea; Plans to Seek FDA Approval by Year-End
A-share Evening Highlights | Iran signals willingness to negotiate! Oil prices plunge, gold rallies
